Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease
Open Access
- 1 July 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 123 (7) , 1365-1379
Abstract
We investigated the role of dopamine neurons in the manifestation of levodopa-induced dyskinesia in a rat model of Parkinson's disease. Daily treatment with a subthreshold dose of levodopa gradually induced abnormal involuntary movements (AIM) in 6-hydroxydopamine-lesioned rats, which included stereotypy and contraversive rotation. After 4 weeks of levodopa treatment, rats with mild and severe AIM were assigned to two treatment subgroups. The graft subgroup received embryonic ventral mesencephalic tissue into the striatum, whilst the sham-graft subgroup received vehicle only. Rats continued to receive levodopa treatment for 3 months post-graft. Brain sections at the level of the basal ganglia were processed for autoradiography using a ligand for dopamine transporter, and in situ hybridization histochemistry for mRNAs encoding postsynaptic markers. Levodopa-induced AIM significantly improved in grafted rats. The severity of AIM correlated inversely with the density of dopamine nerve terminals in the striatum (P < 0.001), with almost no AIM when the density of dopamine nerve terminals was >10–20% of normal. Embryonic dopamine neuronal grafts normalized not only mRNA expression for preproenkephalin (PPE) in the indirect pathway, but also mRNA expression for prodynorphin (PDyn) in the direct pathway, which was upregulated by levodopa treatment. AIM scores correlated linearly with expression of PPE mRNA in the indirect pathway (P < 0.001) and also with PDyn mRNA in the direct pathway (P < 0.001). We conclude that embryonic dopamine neuronal grafts may improve levodopa-induced dyskinesia by restoring altered activities of postsynaptic neurons, resulting not only from dopamine denervation, but also from levodopa therapy, provided that the density of striatal dopaminergic nerve terminals is restored above a `threshold' level.Keywords
This publication has 55 references indexed in Scilit:
- Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's diseaseMovement Disorders, 1998
- Outcome Following Intrastriatal Fetal Mesencephalic Grafts for Parkinson's Patients Is Directly Related to the Volume of Grafted TissueExperimental Neurology, 1997
- Enhancement of the Behavioral Response to Apomorphine Administration Following Repeated Treatment in the 6-Hydroxydopamine-Lesioned Rat Is Temporally Correlated with a Rise in Striatal Preproenkephalin-B, but Not Preproenkephalin-A, Gene ExpressionExperimental Neurology, 1997
- Evidence for long‐term survival and function of dopaminergic grafts in progressive Parkinson's diseaseAnnals of Neurology, 1994
- Clinical application of neuronal grafts in Parkinson's diseaseJournal of Neurology, 1994
- On the Role of Enkephalin Cotransmission in the GABAergic Striatal Efferents to the Globus PallidusExperimental Neurology, 1994
- Normalization of Striatal Proenkephalin and Preprotachykinin mRNA Expression by Fetal Substantia Nigra GraftsExperimental Neurology, 1993
- Transplantation of fetal dopamine neurons in Parkinson's disease: One‐year clinical and neurophysiological observations in two patients with putaminal implantsAnnals of Neurology, 1992
- Effects of opioid agonist drugs on the in vitro release of 3H-GABA, 3H-dopamine and 3H-5HT from slices of rat globus pallidusBiochemical Pharmacology, 1987
- Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine systemBrain Research, 1970